660 results about "Ischemic stroke" patented technology

A thromboembolic removal system for treating ischemic stroke, including a guide and occlusion catheter, a delivery and aspiration catheter, an aspiration pump, a thromboembolic receiver, and a thromboembolic separator.

A thromboembolic removal system for treating ischemic stroke, including a guide and occlusion catheter, a delivery and aspiration catheter, an aspiration pump, a thromboembolic receiver, and a thromboembolic separator.

A thromboembolic removal system for treating ischemic stroke, including a guide and occlusion catheter, a delivery and aspiration catheter, an aspiration pump, a thromboembolic receiver, and a thromboembolic separator.

A system for treatment of ischemic stroke provides a stroke treatment workflow plan defining series of diagnostic actions and therapeutic actions to be performed at locations within a health care facility identified by beacons detectable by proximity sensors that travel with the patient. A first communications device having wireless communications capabilities receives a signal from a proximity sensor and typically transmits data to a second communications device having a visible timer and configured to receive data from and send data to other wireless communications devices. When the a patient undergoes diagnosis and treatment via the workflow plan, the system tracks the location of the patient within the workflow plan and the time at which the patient is at each location, and records the location of the patient and the time of the location within the workflow plan.

A device and a method for increasing or restoring a flow in a body lumen are provided. The device and the method may treat conditions related to a stroke, such as an ischemic stroke, by removing an occlusion from a blood vessel and / or reopen a blood vessel. The device may comprise a tubing compartment, a central wire, and an engaging compartment. The engaging compartment may comprise a distal engaging element and a proximal engaging element. A clot or occlusion present in the body lumen such as an artery may be engaged in and / or between the distal and proximal engaging elements. Further, the positions of one or both of the engaging elements and the distance therebetween can be adjusted to ensure the engagement of the clot or occlusion.

A thromboembolic removal system for treating ischemic stroke includes an elongate member and a receiver on a distal portion of the elongate member. The receiver includes structural members arranged to form a sleeve having a central lumen. A plurality of the structural members form engaging elements having apex regions that extend into the central lumen. During use of the thromboembolic removal system, the receiver is advanced over a body of thromboembolic material within a blood vessel, causing the body to be received into the central lumen, and causing the engaging elements to engage the body within the lumen.

Devices, methods, and systems facilitate and enable treatment of ischemic stroke. More specifically, a tethered basket-like system operates in conjunction with a microcatheter system, to provide arterial support and capture emboli.

A thromboembolic removal system for treating ischemic stroke, including a guide and occlusion catheter, an aspiration catheter, an aspiration pump, and a thromboembolic separator. During aspiration of thromboembolic material through the aspiration catheter, the separator element is advanced from and retracted into the catheter lumen to break up or prevent clogs or flow restrictions formed by the thromboembolic material. Longitudinal channels in the separator allow aspiration through the aspiration catheter to continue even when the separator is disposed in the aspiration catheter lumen.

A device and a method for increasing or restoring a flow in a body lumen are provided. The device and the method may treat conditions related to a stroke, such as an ischemic stroke, by removing an occlusion from a blood vessel and / or reopen a blood vessel. The device may comprise a pusher tube and an expandable compartment. The expandable compartment may comprise a control element, a reconfigurable element, and supportive element. The supportive element is configured to adjust a radial force and a configuration of the reconfigurable element, thereby allowing highly efficient removal of an occlusion from a blood vessel and / or reopen a blood vessel with least or no damage to the body lumen.

An ischemic stroke device includes a telescoping support member, a first or proximal expandable member connected to the telescoping support member, and a second or distal expandable member connected to the first expandable member. A proximal portion of the first expandable member is attached to a distal end of an outer shaft of the telescoping support member, and a distal end of the first expandable member is attached to a distal portion of an inner core wire of the telescoping support member. The proximal end of the second expandable member is permanently joined to the distal end of the inner core wire. The first expandable member everts to cover the second expandable member that is used to capture an obstruction or clot, prior to pulling the obstruction or clot into a catheter for removal from a patient's vasculature.

Partial or total occlusions of fluid passages within the human body are removed by positioning an array of optical fibers in the passage and directing treatment radiation pulses along the fibers, one at a time, to generate a shock wave and hydrodynamic flows that strike and emulsify the occlusions. A preferred application is the removal of blood clots (thrombi and emboli) from small cerebral vessels to reverse the effects of an ischemic stroke. The operating parameters and techniques are chosen to minimize the amount of heating of the fragile cerebral vessel walls occurring during this photoacoustic treatment. One such technique is the optical monitoring of the existence of hydrodynamic flow generating vapor bubbles when they are expected to occur and stopping the heat generating pulses propagated along an optical fiber that is not generating such bubbles.

Stimulation of the facial nerve system (e.g., electrically, electromagnetically, etc.) in ischemic stroke patients will cause dilation of occluded arteries and dilation of surrounding arteries, allowing for blood flow to circumvent the obstruction and reach previously-deprived tissue. The device approaches the facial nerve and its branches in the vicinity of the ear. In use, the device can be inserted into the ear canal and / or placed in proximity to the ear in order to stimulate the facial nerve system non-invasively (e.g., using an electromagnetic field). The device can be used in the emergency treatment of acute stroke or chronically variations for long-term maintenance of blood flow to the brain and stroke prevention. Additional embodiments of the device may be adapted for use on different regions of the body.

Devices, systems and methods are disclosed that allow a patient to self-treat neurodegenerative diseases, such as dementia, Alzheimer's disease, ischemic stroke, post-concussion syndrome, chronic traumatic encephalopathy and the like by electrical noninvasive stimulation of a vagus nerve. The system comprises a handheld stimulator that is applied to the surface of the patient's neck, wherein the stimulator comprises or is joined to a smartphone. A camera of the smartphone may be used to position and reposition the stimulator to a particular location on the patient's neck. The system may also comprise a base station that is used to meter the charging of a rechargeable battery within the stimulator. The base station and stimulator transmit data to one another regarding the status of a stimulation session.

A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and transmitting ultrasound from the transmitter into the intracranial space, wherein the Mechanical Index of ultrasound energy traveling through cerebral tissue in the intracranial space is less than 1.0, the power intensity delivered to a target tissue in the intracranial space is greater than 50 mW / cm2 and less than 200 mW / cm2, and the frequency of the transmitted ultrasound is within the range between 500 kHz and 2 MHz. Microbubbles, aspirin, both microbubbles and aspirin, and a mixture of microbubbles and aspirin, can also be delivered into the intracranial space.

A clot removal device has a segment that has two main struts that serve as a frame for holding a plurality of secondary struts. Each of the two main struts has a proximal end that is connected at a proximal point of the segment and extends along a generally circumferential path, with each main strut terminating at a separate connecting point that is distal from the proximal point. The connecting points are connected to each other to form a generally tubular structure defining an inner lumen. The plurality of secondary struts forms a lattice of cells, with each cell surrounded by four secondary struts. Two generally straight distal struts are connected to the lattice of cells at a distal end of the segment, and are connected to each other to form a distal point. A distal opening is defined by the cells adjacent the distal struts, the distal opening communicating with the lumen and terminating at the proximal point.

The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and Polygeline (haemaccel). Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and transmitting ultrasound from the transmitter into the intracranial space, wherein the Mechanical Index of ultrasound energy traveling through cerebral tissue in the intracranial space is less than 1.0, the power intensity delivered to a target tissue in the intracranial space is greater than 50 mW / cm2 and less than 200 mW / cm2, and the frequency of the transmitted ultrasound is within the range between 500 kHz and 2 MHz. Microbubbles, aspirin, both microbubbles and aspirin, and a mixture of microbubbles and aspirin, can also be delivered into the intracranial space.

The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptors. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

Systems for treatment of ischemic stroke can include tethered baskets. A basket can be tethered to a pusher or elongate member. A temporary reperfusion device or temporary capture device also can be tethered to the pusher or elongate member.

The invention discloses a micro-molecule polypeptide TAT-p53DM and an application thereof to preparing a medicine for treating or preventing ischemic stroke. A fusion protein polypeptide TAT-p53DM of a TAT protein transduction domain and p53DM is artificially synthesized; TAT carries p53DM protein polypeptide to pass through a blood brain barrier through blood so as to be taken by nerve cells; used in an in-vitro and in-vivo ischemic stroke model, the micro-molecule polypeptide TAT-p53DM is capable of effectively playing a biological role in blocking binding between death domain of death associated protein kinase 1 (DAPK1DD) and tumor suppression protein p53DNA binding motifs (p53DM), inhibiting signals capable of causing neuronal apoptosis and necrosis at DAPK1 downstream, and reducing ischemic stroke brain injury; moreover, molecular targets are provided for further developing medicines for clinically treating ischemic stroke.

The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.

The invention relates to a composite of active ingredients of Chinese herb medicine used for preventing the damage of cerebral ischemia and relevant diseases, in particular to a preparation which is prepared by the active ingredients of the Chinese herb medicine; the preparation is prepared by the active ingredients of the Chinese herb medicine and the conventional preparation technique which is used by carriers permitted by pharmacy, and comprises the following components with the parts by weight: 2 to 10 parts of ginsenoside Rb, 2 to 10 parts of ginsenoside Rg1, 1 to 5 parts of ginsenoside Rd, 1 to 5 parts of ginsenoside Re, 2 to 10 parts of stilbene glycoside, 1 to 5 parts of ginkgolide and 1 to 5 parts of flavonoid mixture which consists of kaempferol and quercetin with the weight rate to be 1:1. The invention has the advantages that the defects that in the traditional compounded Chinese medicine, the composition is complex, the product quality is not controlled effectively and the curative effect is not stable are overcome, has clear ingredients, definite effect, stable quality and obvious control effect on ischemic stroke, sequela, cerebral arteriosclerosis and vascular dementia, can improve the functions of motor nerve, and learning and memory of the patients, has low toxicity and simple preparation method without obvious side effect and is suitable for industrial mass production.

The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.

A Chinese medicine in the form of injection for treating the acute stage of ischemic apoplexy and cerebral embolism is prepared from 3 Chinese-medicinal materials; red sage root, red peony root and grass-leaved sweetflag rhizome. Its advantage is high curative effect.

Several embodiments of the invention relate to systems and methods for removing compositions comprising dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same. In several embodiments, the systems include activated carbon filters, adsorbents, odor adsorbing fabrics, masks, clean air members and clean air supply assemblies. Methods for reducing the concentration of a DMSO metabolite, or the odors associated with said DMSO metabolite are provided in some embodiments. In some embodiments the systems and methods facilitating the treatment of traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses with compositions comprising DMSO.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Fusion proteins comprising a single chain antigen-binding domain (scFv) of a monoclonal antibody, linked to an anti-thrombotic agent, anti-inflammatory agent, or a pro-drug thereof are provided, where the polypeptide binds to a binding site (antigen) expressed on the surface of a red blood cell at a density greater than 5,000 copies per red blood cell. Pharmaceutical compositions comprising these fusion proteins, and methods of delivering an anti-thrombotic agent to the surface of a red blood cell via delivery of these fusion proteins, and methods of treating or preventing thrombosis, tissue ischemia, acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease via administration of the fusion proteins or compositions comprising same are also provided.

An embolization device for treating ischemic stroke is disclosed, having a surface, wherein the body portion is configured to have a radiopaque and electropositive surface under physiological conditions when the device is emplaced, which ionically binds a blood component in an amount effective to promote stability of device in situ to bind to a tissue component in an amount effective to increase adhesion of the device as compared to a device without an electropositive surface. Embolic coils being so delivered are electrolytically detachable in under 10 seconds, according to the disclosed vascular implant systems.